The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target

Cell Cycle

Volumn 13, Issue 6, 2014, Pages 1041-1048

  Pan, Lu Zhe ^a,c   Ahn, Dae Gyun ^a   Sharif, Tanveer ^a   Clements, Derek ^a   Gujar, Shashi A ^a,b   Lee, Patrick W K ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b IWK HEALTH CENTRE   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Apoptosis; NMNAT 2; p53

Indexed keywords

DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE; NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE 2; NUTLIN 3; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; BIOSYNTHESIS; CELL FATE; CELL METABOLISM; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA DAMAGE; ENERGY YIELD; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOTIDE METABOLISM; PROTEIN EXPRESSION; PROTEIN TARGETING;

APOPTOSIS; NAD+ BIOSYNTHESIS; NMNAT-2; P53;

BINDING SITES; CELL DEATH; CELL LINE, TUMOR; DNA DAMAGE; HUMANS; NAD; NICOTINAMIDE-NUCLEOTIDE ADENYLYLTRANSFERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897997735     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.28128     Document Type: Article

References (60)

1. Di Stefano G, Manerba M, Vettraino M. NAD metabolism and functions: a common therapeutic target for neoplastic, metabolic and neurodegenerative diseases. Curr Top Med Chem 2013; 13:2918-29; PMID:24171774
2. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403:795-800; PMID:10693811; http://dx.doi.org/10.1038/35001622
3. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, Deng CX, Finkel T. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA 2008; 105:14447-52; PMID:18794531; http://dx.doi.org/10.1073/pnas.0803790105
4. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S, Ilkayeva OR, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010; 464:121-5; PMID:20203611; http://dx.doi.org/10.1038/nature08778
5. van der Horst A, Tertoolen LG, de Vries-Smits LM, Frye RA, Medema RH, Burgering BM; van der HA. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem 2004; 279:28873-9; PMID:15126506; http://dx.doi.org/10.1074/jbc.M401138200
6. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107:149-59; PMID:11672523; http://dx.doi.org/10.1016/S0092-8674(01)00527- X
7. Wang ZQ, Stingl L, Morrison C, Jantsch M, Los M, Schulze-Osthoff K, Wagner EF. PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 1997; 11:2347-58; PMID:9308963; http://dx.doi.org/10.1101/gad.11.18. 2347
8. de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, Oliver FJ, Masson M, Dierich A, LeMeur M, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997; 94:7303-7; PMID:9207086; http://dx.doi.org/10.1073/pnas.94.14.7303
9. Kim H, Jacobson EL, Jacobson MK. Synthesis and degradation of cyclic ADP-ribose by NAD glycohydrolases. Science 1993; 261:1330-3; PMID:8395705; http://dx.doi.org/10.1126/science.8395705
10. Howard M, Grimaldi JC, Bazan JF, Lund FE, Santos-Argumedo L, Parkhouse RM, Walseth TF, Lee HC. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science 1993; 262:1056-9; PMID:8235624; http://dx.doi.org/10.1126/science.8235624
11. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124:269-70; PMID:13351639
12. Heikal AA. Intracellular coenzymes as natural biomarkers for metabolic activities and mitochondrial anomalies. Biomark Med 2010; 4:241-63; PMID:20406068; http://dx.doi.org/10.2217/bmm.10.1
13. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7:11-20; PMID:18177721; http://dx.doi.org/10.1016/j.cmet.2007.10.002
14. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-12; PMID:18431400; http://dx.doi.org/10.1038/nrm2395
15. Brady CA, Attardi LD. p53 at a glance. J Cell Sci 2010; 123:2527-32; PMID:20940128; http://dx.doi.org/10.1242/jcs.064501
16. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413-31; PMID:19410540; http://dx.doi.org/10.1016/j.cell. 2009.04.037
17. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer 2009; 9:724-37; PMID:19776742; http://dx.doi.org/10.1038/nrc2730
18. Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH. Metabolic regulation by p53 family members. Cell Metab 2013; 18:617-33; PMID:23954639; http://dx.doi.org/10.1016/j.cmet.2013.06.019
19. Lago CU, Sung HJ, Ma W, Wang PY, Hwang PM. p53, aerobic metabolism, and cancer. Antioxid Redox Signal 2011; 15:1739-48; PMID:20919942; http://dx.doi.org/10.1089/ars.2010.3650
20. Mathupala SP, Heese C, Pedersen PL. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 1997; 272:22776-80; PMID:9278438; http://dx.doi.org/10.1074/jbc.272.36.22776
21. Cheung EC, Vousden KH. The role of p53 in glucose metabolism. Curr Opin Cell Biol 2010; 22:186-91; PMID:20061129; http://dx.doi.org/10.1016/j.ceb.2009. 12.006
22. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer 2009; 9:691-700; PMID:19759539; http://dx.doi.org/10.1038/nrc2715
23. Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci USA 2004; 101:2259-64; PMID:14982997; http://dx.doi.org/10.1073/pnas. 0308762101
24. Simbulan-Rosenthal CM, Rosenthal DS, Luo RB, Samara R, Jung M, Dritschilo A, Spoonde A, Smulson ME. Poly(ADP-ribosyl)ation of p53 in vitro and in vivo modulates binding to its DNA consensus sequence. Neoplasia 2001; 3:179-88; PMID:11494111; http://dx.doi.org/10.1038/sj.neo.7900155
25. Lee MH, Na H, Kim EJ, Lee HW, Lee MO. Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1. Oncogene 2012; 31:5099-107; PMID:22286760; http://dx.doi.org/10.1038/onc.2012.2
26. Valenzuela MT, Guerrero R, Núñez MI, Ruiz De Almodóvar JM, Sarker M, de Murcia G, Oliver FJ. PARP-1 modifies the effectiveness of p53-mediated DNA damage response. Oncogene 2002; 21:1108-16; PMID:11850828; http://dx.doi.org/10.1038/sj.onc.1205169
27. Sauve AA. NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther 2008; 324:883-93; PMID:18165311; http://dx.doi.org/10.1124/jpet.107. 120758
28. Berger F, Lau C, Dahlmann M, Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J Biol Chem 2005; 280:36334-41; PMID:16118205; http://dx.doi.org/10.1074/jbc.M508660200
29. Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science 2009; 324:654-7; PMID:19286518; http://dx.doi.org/10.1126/science.1170803
30. Zhang T, Berrocal JG, Frizzell KM, Gamble MJ, DuMond ME, Krishnakumar R, Yang T, Sauve AA, Kraus WL. Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters. J Biol Chem 2009; 284:20408-17; PMID:19478080; http://dx.doi.org/10.1074/jbc.M109.016469
31. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8; PMID:14704432; http://dx.doi.org/10.1126/science.1092472
32. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1:45-9; PMID:1301998; http://dx.doi.org/10.1038/ng0492-45
33. Hoh J, Jin S, Parrado T, Edington J, Levine AJ, Ott J. The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci USA 2002; 99:8467-72; PMID:12077306; http://dx.doi.org/10.1073/pnas. 132268899
34. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126:107-20; PMID:16839880; http://dx.doi.org/10.1016/j.cell.2006.05. 036
35. Thornborrow EC, Patel S, Mastropietro AE, Schwartzfarb EM, Manfredi JJ. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. Oncogene 2002; 21:990-9; PMID:11850816; http://dx.doi.org/10.1038/sj.onc.1205069
36. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 1995; 23:2584-92; PMID:7651818; http://dx.doi.org/10.1093/nar/ 23.14.2584
37. Dang CV. Links between metabolism and cancer. Genes Dev 2012; 26:877-90; PMID:22549953; http://dx.doi.org/10.1101/gad.189365.112
38. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11:85-95; PMID:21258394; http://dx.doi.org/10.1038/nrc2981
39. Curtis R, Geesaman BJ, DiStefano PS. Ageing and metabolism: drug discovery opportunities. Nat Rev Drug Discov 2005; 4:569-80; PMID:15976816; http://dx.doi.org/10.1038/nrd1777
40. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7:517-28; PMID:16829982; http://dx.doi.org/10.1038/nrm1963
41. Verdin E. The Many Faces of Sirtuins: Coupling of NAD metabolism, sirtuins and lifespan. Nat Med 2014; 20:25-7; PMID:24398962; http://dx.doi.org/10.1038/nm.3447
42. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13:83-96; PMID:23303139; http://dx.doi.org/10. 1038/nrc3430
43. Herskovits AZ, Guarente L. Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res 2013; 23:746-58; PMID:23689277; http://dx.doi.org/ 10.1038/cr.2013.70
44. Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: the critical roles of p53. Oncogene 2013; 32:5129-43; PMID:23416979; http://dx.doi.org/10.1038/onc.2012.640
45. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell 2006; 126:257-68; PMID:16873059; http://dx.doi.org/10.1016/j.cell.2006.07.002
46. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, et al. de CR, Rolo AP, Turner N, Bell EL, and Sinclair DA. Declining NAD(+) Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during. Aging Cell 2013; 155:1624-38; http://dx.doi.org/10.1016/j.cell.2013.11.037
47. Akeno N, Miller AL, Ma X, Wikenheiser-Brokamp KA. p53 suppresses carcinoma progression by inhibiting mTOR pathway activation. Oncogene 2014; PMID:24469052; http://dx.doi.org/10.1038/onc.2013.589
48. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008; 134:451-60; PMID:18692468; http://dx.doi.org/10.1016/j.cell.2008.06.028
49. Serrano M. Shifting senescence into quiescence by turning up p53. Cell Cycle 2010; 9:4256-7; PMID:20980826; http://dx.doi.org/10.4161/cc.9.21.13785
50. Leontieva OV, Gudkov AV, Blagosklonny MV. Weak p53 permits senescence during cell cycle arrest. Cell Cycle 2010; 9:4323-7; PMID:21051933; http://dx.doi.org/10.4161/cc.9.21.13584
51. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci USA 2010; 107:9660-4; PMID:20457898; http://dx.doi.org/10.1073/pnas.1002298107
52. Gilley J, Coleman MP. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol 2010; 8:e1000300; PMID:20126265; http://dx.doi.org/10.1371/journal.pbio.1000300
53. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010; 67:953-66; PMID:20869593; http://dx.doi.org/10.1016/j.neuron.2010.08.044
54. Yan T, Feng Y, Zheng J, Ge X, Zhang Y, Wu D, Zhao J, Zhai Q. Nmnat2 delays axon degeneration in superior cervical ganglia dependent on its NAD synthesis activity. Neurochem Int 2010; 56:101-6; PMID:19778564; http://dx.doi.org/10.1016/j.neuint.2009.09.007
55. Gan L, Mucke L. Paths of convergence: sirtuins in aging and neurodegeneration. Neuron 2008; 58:10-4; PMID:18400158; http://dx.doi.org/10. 1016/j.neuron.2008.03.015
56. Ali YO, Ruan K, Zhai RG. NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy. Hum Mol Genet 2012; 21:237-50; PMID:21965302; http://dx.doi.org/10.1093/hmg/ddr449
57. Hicks AN, Lorenzetti D, Gilley J, Lu B, Andersson KE, Miligan C, Overbeek PA, Oppenheim R, Bishop CE. Nicotinamide mononucleotide adenylyltransferase 2 (Nmnat2) regulates axon integrity in the mouse embryo. PLoS One 2012; 7:e47869; PMID:23082226; http://dx.doi.org/10.1371/journal.pone.0047869
58. Ljungberg MC, Ali YO, Zhu J, Wu CS, Oka K, Zhai RG, Lu HC. CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy. Hum Mol Genet 2012; 21:251-67; PMID:22027994; http://dx.doi.org/10.1093/hmg/ ddr492
59. Mattia M, Gottifredi V, McKinney K, Prives C. p53-Dependent p21 mRNA elongation is impaired when DNA replication is stalled. Mol Cell Biol 2007; 27:1309-20; PMID:17158927; http://dx.doi.org/10.1128/MCB.01520-06
60. Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 2002; 99:95-100; PMID:11756653; http://dx.doi.org/10. 1073/pnas.012283399